The promotion of olanzapine in primary care: an examination of internal industry documents

Social Science & Medicine
Glen I Spielmans

Abstract

Media reports have discussed how olanzapine was marketed off-label for dementia and subsyndromal bipolar disorder. Much of this marketing occurred in primary care settings. However, these reports have provided few details. In legal proceedings, Lilly disclosed internal documents that detail the strategies utilized to market olanzapine. The current paper addresses the marketing of olanzapine in detail based upon a review of these documents. All 358 documents released by Lilly are publicly available online. Documents were utilized for this review if they were relevant to the marketing of olanzapine in primary care settings in the United States. It was found that olanzapine was marketed off-label in primary care settings for relatively mild symptoms that were framed as bipolar disorder and schizophrenia. A key strategy in this campaign was the use of hypothetical patient profiles in detailing visits, most of which clearly failed to meet diagnostic criteria for any recognized mental disorder. Evidence emerged that olanzapine was also marketed off-label as a treatment for dementia.

References

Jul 24, 1996·JAMA : the Journal of the American Medical Association·M M WeissmanE K Yeh
Jan 28, 2004·The Journal of Clinical Psychiatry·Michael P Bogenschutz, H George Nurnberg
Mar 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lon S SchneiderPhilip S Insel
Apr 7, 2006·PLoS Medicine·Steven Woloshin, Lisa M Schwartz
Apr 7, 2006·PLoS Medicine·Ray Moynihan, David Henry
Aug 16, 2006·Annals of Internal Medicine·Michael A SteinmanC Seth Landefeld
Oct 13, 2006·The New England Journal of Medicine·Lon S SchneiderUNKNOWN CATIE-AD Study Group
Nov 17, 2006·The Journal of Clinical Psychiatry·Benedicto Crespo-FacorroJosé Luis Vázquez-Barquero
Dec 19, 2007·Psychotherapy and Psychosomatics·Glen I Spielmans

❮ Previous
Next ❯

Citations

Jan 15, 2011·American Journal of Public Health·Howard Brody, Donald W Light
Aug 20, 2010·Anthropology & Medicine·Jeffrey Longhofer, Jerry Floersch
Dec 14, 2011·Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen·Wilhelm Niebling
Mar 22, 2012·Internal Medicine Journal·N GhineaR Day
Jul 13, 2012·Globalization and Health·Joel Lexchin
Apr 9, 2014·Transcultural Psychiatry·Joanna Moncrieff
Dec 22, 2010·Journal of Health and Social Behavior·Stefan Timmermans, Hyeyoung Oh
Jun 2, 2012·The Journal of Nervous and Mental Disease·Laura Batstra, Allen Frances
Jun 4, 2010·Academic Medicine : Journal of the Association of American Medical Colleges·Frederick S Sierles
Apr 26, 2012·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·James Nicholls
Jan 4, 2013·Journal of Paediatrics and Child Health·Mike Daube
Oct 29, 2019·JAMA Internal Medicine·Alexander C EgilmanAmy Kapczynski
Apr 18, 2014·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Rebecca SearleDavid P French
Oct 22, 2015·Journal of Clinical Psychopharmacology·Christopher J MillerMark S Bauer
Sep 7, 2017·Trends in psychiatry and psychotherapy·Christopher Izehinosen Okpataku, David Tawani
Dec 24, 2009·The Medical Journal of Australia·Peter I Parry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.